Spruce Biosciences Inc
SPRB
Get informed when a big investor buys or sells
+ FollowMarket Cap$59.74M
Close$
$62.84
40.9% upside
Current Fair Value
40.9% upsideUndervalued by 40.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $59.74 Million |
|---|---|
| Enterprise Value | $7.32 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-50.83 |
| Beta | 3.21 |
| Outstanding Shares | 1,372,084 |
Return
| Return on Equity | -107.34% |
|---|---|
| Return on Assets | -66.22% |
| Return on Invested Capital | -77.72% |
Valuation & Multiples
| P/E Ratio | -1.16 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 1.78 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.21 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.23 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-7.32
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-5.79
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 53.92%▼ 79.97% |
|---|---|
| Total Invested | $48.34M▼ 26.30% |
| Investors Holding | 320% |
ESG Score
No data
About Spruce Biosciences Inc
17 employeesSpruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product cand...